AZD-7687

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H25N3O3
Molecular Weight	367.4415
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=NC(C)=C(N=C1C2=CC=C(C=C2)[C@H]3CC[C@H](CC(O)=O)CC3)C(N)=O

InChI

InChIKey=YXFNPRHZMOGREC-SHTZXODSSA-N

InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)/t14-,15-

HIDE SMILES / InChI

Description

AZD-7687 is a potent inhibitor of Diacylglycerol O-acyltransferase 1 (DGAT1) which was developed by AstraZeneca for the treatment obesity and type 2 diabetes mellitus. AZD-7687 reached phase I of clinical trials, but was discontinued by unknown reasons.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Diacylglycerol O-acyltransferase 1 7	Inhibitor 8,504		0.08 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 206	Primary		Phase I 438	Unknown
Type 2 diabetes mellitus 262	Primary		Phase I 438	Unknown

C_max

Value	Dose	Analyte	Population
3.5 μM	20 mg single, oral	AZD-7687 plasma	Homo sapiens
2.9 μM	20 mg single, oral	AZD-7687 plasma	Homo sapiens
12 μM	60 mg single, oral	AZD-7687 plasma	Homo sapiens
0.96 μM	5 mg single, oral	AZD-7687 plasma	Homo sapiens
1.9 μM	10 mg single, oral	AZD-7687 plasma	Homo sapiens
0.92 μM	5 mg single, oral	AZD-7687 plasma	Homo sapiens
1.6 μM	10 mg single, oral	AZD-7687 plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
43 μM × h	20 mg single, oral	AZD-7687 plasma	Homo sapiens
33 μM × h	20 mg single, oral	AZD-7687 plasma	Homo sapiens
110 μM × h	60 mg single, oral	AZD-7687 plasma	Homo sapiens
11 μM × h	5 mg single, oral	AZD-7687 plasma	Homo sapiens
19 μM × h	10 mg single, oral	AZD-7687 plasma	Homo sapiens
11 μM × h	5 mg single, oral	AZD-7687 plasma	Homo sapiens
18 μM × h	10 mg single, oral	AZD-7687 plasma	Homo sapiens

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2,252	inhibitor 2,438	inhibitor 2,507	inhibitor 2,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2,153 CYP2C19 2,057 P-gp 1,741	Human hepatocytes 3

Drug as perpetrator

Show entries

Target	Modality	Activity
P-gp 1,932	inhibitor 4,027	inconclusive [IC50 20.5962 uM]
CYP1A2 2,333	inhibitor 4,027	no [IC50 >30 uM]
CYP2C19 2,141	inhibitor 4,027	no [IC50 >30 uM]
CYP2C9 2,497	inhibitor 4,027	no [IC50 >30 uM]
CYP2D6 2,546	inhibitor 4,027	no [IC50 >30 uM]

Showing 1 to 5 of 6 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
Human hepatocytes 3	substrate 4,014	no

Showing 1 to 1 of 1 entries

Previous1Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2,263	inhibitor 2,237

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008TUG	https://www.1pchem.com/search?query=1P008TUG
eMolecules	195178693	https://orderbb.emolecules.com/search/#?query=195178693
eMolecules	300752917	https://orderbb.emolecules.com/search/#?query=300752917
Lan Pharmatech	LQT-B38840
MolPort	MolPort-046-702-037	https://www.molport.com/shop/molecule-link/MolPort-046-702-037

Showing 1 to 5 of 6 entries

Previous1 2Next

PubMed

Show entries

Title	Date	PubMed
Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).	2012 Dec 13	23116186

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Multiple doses of AZD-7687 (1, 2.5, 5, 10 and 20 mg/day) were administered for 1 week.

Route of Administration: Oral

In Vitro Use Guide

Human adipose tissue was incubated with 200 uL of DMEM (6 mM glucose, 5% FCS, 0.5% penicillin/streptomycin) containing AZD-7687 dissolved in DMSO (0.1% final concentration) for 30 min at 37C, 5% CO2. AZD-7687 inhibited TAG synthesis in human adipose tissue with IC50 value of 0.01 uM.

Show entries

Name

Type

Language

AZD7687

Preferred Name

English

AZD-7687

Common Name

English

CYCLOHEXANEACETIC ACID, 4-(4-(6-(AMINOCARBONYL)-3,5-DIMETHYL-2-PYRAZINYL)PHENYL)-, TRANS-

Common Name

English

AZD 7687 [WHO-DD]

Common Name

English

TRANS-4-(4-(6-(AMINOCARBONYL)-3,5-DIMETHYL-2-PYRAZINYL)PHENYL)CYCLOHEXANEACETIC ACID

Systematic Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

6QTJ9P2NYT

PRIMARY

DRUG BANK

DB14949

PRIMARY

PUBCHEM

42636350

PRIMARY

EPA CompTox

DTXSID60655297

PRIMARY

SMS_ID

300000056614

PRIMARY

Showing 1 to 5 of 6 entries

Previous1 2Next

ACTIVE MOIETY


					6QTJ9P2NYT

AZD-7687

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

Drug as perpetrator